Valneva (VALN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Valneva has announced promising three-year data for its single-dose chikungunya vaccine, IXCHIQ®, which maintains strong antibody levels in both younger and older adults. The vaccine is approved in the US, Europe, and Canada, and Valneva is working to expand its use to adolescents and in regions with limited vaccine access. Supported by significant funding, the company is also pursuing marketing authorization in Brazil and aims to broaden access in low and middle-income countries.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
